Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases

Reuters

Jan 12

<a href="https://laohu8.com/S/LXEO">Lexeo Therapeutics</a> Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases

Lexeo Therapeutics Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602851297"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602851297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602851297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602851297","market":"nz","top_or_hot":-1,"title":"Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexeo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexeo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXEO","symbol_name":"Lexeo Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6fN3M6:1","article_id":"2602851297","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602851297","pubTimestamp":1768220737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexeo Therapeutics Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LXEO":"Lexeo Therapeutics","BK4139":"生物科技"},"translate_title":"Lexeo Therapeutics推出针对遗传性心脏病的心脏基因治疗管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXEO":0.9},"content_text":"Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases\n    \n\n        Lexeo Therapeutics Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}